Sarclisa (Isatuximab-irfc)

Sarclisa is a CD38-directed cytolytic antibody used, along with medicines pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have previously received at least a couple of therapies including a drug lenalidomide and a proteasome inhibitor. 

Recommended Dosage: The recommended dose is 10 mg/kg as an intravenous infusion every week for 4 weeks followed by every 2 weeks along with pomalidomide and dexamethasone until the disease is progressive or in case of unacceptable toxicity. Each treatment cycle typically consists of a 28-day period. If a planned dose of sarclisa injection is missed, administer the dose as promptly as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.

• Use of injection isatuximab-irfc 100 mg / 500 mg is restricted in patients with severe hypersensitivity to isatuximab-irfc or to any of its existing excipients. 
• Infusion-related reactions have been observed in patients treated with isatuximab-irfc. To reduce the risk and severity of infusion-related reactions, premedicate patients before isatuximab-irfc infusion with acetaminophen, diphenhydramine, H2 antagonists, or equivalent; dexamethasone. 
• The sarclisa 100 mg injection may cause neutropenia. Monitor CBC counts periodically during treatment. Consider the use of antibiotics and antiviral prophylaxis while on treatment. Asess patients with neutropenia for signs/symptoms of infection. 
• Monitor vital signs/symptoms frequently while on the entire isatuximab infusion. For patients with grade 1/2 reactions, interrupt isatuximab infusion and provide apt medical assistance. 
• On behalf of the mechanism of action, sarclisa 500 mg or 100 mg can cause fetal harm if administered to a pregnant woman. This medicine may cause fetal immune cell depletion and reduction in bone density. 
• In some cases, second primary malignancies were reported. Patients should be monitored for the development of second primary malignancies, as per IMWG guidelines. 

What documents are required to import SARCLISA to India?

SARCLISA (isatuximab-irfc) injection can be imported by patients or government hospitals on the name of the patients only.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by Government of India).

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from the doctor.
• Import permit, if applicable.

Is SARCLISA available in India?

SARCLISA (isatuximab-irfc injection) is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). We provide:

• Information on availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune etc.).
• Medicine pricing.
• Finding a genuine and reliable source from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

SARCLISA can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

Urgent Meds can facilitate the supply of SARCLISA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for SARCLISA pricing in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing SARCLISA (Medicines from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Sarclisa®?

Isatuximab-irfc is the Generic Name for the trade name drug Sarclisa®.

What is the Manufacturer Name of Sarclisa®?

Sarclisa® is manufactured by Sanofi.

Is Sarclisa® approved by the FDA?

Yes, Sarclisa® is approved by the FDA. Date of approval: March 31, 2021.

What is Sarclisa®?

Sarclisa® (isatuximab injection) is a new anti-CD38 monoclonal antibody medication specifically approved for use in treating multiple myeloma (MM).

What is the dosage and form of Sarclisa® supplied?

Sarclisa® is supplied as injections:

• 100 mg/5 mL (20 mg/mL)
• 500 mg/25 mL (20 mg/mL) for intravenous administration.

What are the most common side effects due to Sarclisa®?

Most common side effects due to Sarclisa® include: upper respiratory tract infection, neutropenia, infusion-related reactions, pneumonia, and diarrhea.

How much does Sarclisa cost in India?

The Sarclisa cost in India is very reasonable. To procure this multiple myeloma medicine authentically, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Sarclisa®?

Store the vials of Sarclisa in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze or shake.